{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:21:35Z","timestamp":1788880895169,"version":"build-2803163510"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Huntington's Disease"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder. Clinical features encompass a broad spectrum of movement disorders, psychiatric and cognitive symptoms, often progressing to dementia and imposing a substantial burden on patients and their families. While cholinesterase inhibitors and memantine are often used for symptomatic treatment of Alzheimer's Disease and other dementias, there is currently no approved medication for treating cognitive symptoms in HD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aim to review, summarize, and appraise evidence from the literature for the use of cholinesterase inhibitors and memantine in the treatment of cognitive symptoms in patients with HD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A searched was conducted in PubMed and SCOPUS, from inception until February 2024, for Randomized Clinical Trials (RCTs), open-label, and case-control studies. Quality appraisal was performed using ROBINS-I and ROB2 for non-randomized studies and RCTs, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five eligible studies (three RCTs, one extension study, and one retrospective case-control), exploring the use of rivastigmine (n\u2009=\u20093), memantine (n\u2009=\u20091), and donepezil (n\u2009=\u20091) were found. Only two had a follow-up period longer than eight months. Previous cognitive functioning was not specified in three out of five studies. Cognitive measures varied widely, with Unified Huntington's Disease Rating Scale and Mini-Mental State Exam being used more frequently. None of the studies showed a significant improvement in cognitive function. Side effects occurred in up to 50% of patients and were usually considered mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is insufficient evidence in the literature to support the use of cholinesterase inhibitors or memantine for cognitive symptoms in patients with HD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/18796397251367689","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T07:56:38Z","timestamp":1754985398000},"page":"331-339","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: A systematic review"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5529-717X","authenticated-orcid":false,"given":"Catarina Correia","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias, \rHospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, \rLisbon, Portugal"},{"name":"Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Instituto Gulbenkian de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5385-0901","authenticated-orcid":false,"given":"Vanessa","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias, \rHospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, \rLisbon, Portugal"},{"name":"Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Instituto Gulbenkian de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-8834","authenticated-orcid":false,"given":"Filipa Dourado","family":"Sotero","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias, \rHospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, \rLisbon, Portugal"},{"name":"Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Laborat\u00f3rio de Estudos de Linguagem da Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Mulroy","sequence":"additional","affiliation":[{"name":"Department of clinical and movement neurosciences, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8422-0494","authenticated-orcid":false,"given":"Leonor Correia","family":"Guedes","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Neurologia, Departamento de Neuroci\u00eancias, \rHospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, \rLisbon, Portugal"},{"name":"Centro de Estudos Egas Moniz, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"},{"name":"Instituto Gulbenkian de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13413"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2008.03.006"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25864"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-71779-1_1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116523"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666180302115032"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801893-4.00006-7"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28855"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238106.10423.00"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000240945.44370.f0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20235"},{"key":"e_1_3_2_13_2","first-page":"239","article-title":"Cognitive function in early clinical phase huntington disease after rivastigmine treatment","volume":"26","author":"Se\u0161ok S","year":"2014","unstructured":"Se\u0161ok S, Bolle N, Kobal J, et al. Cognitive function in early clinical phase huntington disease after rivastigmine treatment. Psychiatr Danub 2014; 26: 239\u2013248.","journal-title":"Psychiatr Danub"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.13763"},{"key":"e_1_3_2_15_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/103.1.179"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041470"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.678652"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27227"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-140111"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1988.tb01807.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25964"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2473055"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1191718"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397251367689","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/18796397251367689","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/18796397251367689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:56:37Z","timestamp":1777452997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/18796397251367689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/18796397251367689"],"URL":"https:\/\/doi.org\/10.1177\/18796397251367689","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}